You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):共95個產品納入2021年醫保目錄 新進入品種1個
格隆匯 12-03 16:03

格隆匯12月3日丨海正藥業(600267.SH)公佈,2021123日,國家醫療保障局、人力資源社會保障部發佈了《關於印<國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)>的通知》(醫保發[2021]50)公司產品海博麥布片新進入2021年醫保目“協議期內談判藥品部分”。經統計,公司全資子公司瀚暉製藥有限公司(瀚暉製藥)共有95個產品納入本次2021年醫保目錄其中海正藥業新進入的品種1調出0個,瀚暉製藥無產品新進或調出

進入品種海博麥布片是公司自主研發的首個小分子創新藥,是國內首個、全球第二個口服腸道膽固醇吸收抑制劑201919日,國家藥品監督管理局藥品審評中心受理了公司遞交的海博麥布片的藥品註冊申請公司於2021628到國家藥品監督管理局核准簽發的海博麥布片的《藥品註冊證書》由於海博麥布片上市時間較短,截至目前尚未實現大規模銷售

《2021年醫保目錄》將於2022年1月1日起正式執行,雙方約定的海博麥布片醫保支付標準有效期為2022年1月1日至2023年12月31日。此次公司海博麥布片新進入《2021年醫保目錄》,將有利於該產品的市場銷售,本報吿期內不會對公司的經營業績造成重大影響,未來對公司經營業績的影響尚存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account